Colonic Diseases, Colorectal Cancer, Colorectal Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Site, RAS and BRAF Wild-type, Rectal Diseases
Conditions
Brief summary
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with Metastatic Colorectal Carcinoma(CRC) as 1st Therapy. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with CAPEOX in treatment of patients with mCRC. The patients who are pathologically confirmed as RAS and BRAF wild-type mCRC will be enrolled. Condition or disease Invention/treatment Phase Colorectal Cancer Drug: Anlotinib Hydrochloride Drug: Capecitabine Drug: Oxaliplatin Phase 2
Detailed description
This is an Open, Single Arm, Exploratory and Phase II Clinical Trial of Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF wild-type patients with Metastatic Colorectal Carcinoma(CRC) as 1st Therapy. After 6 cycles of combined therapy, patients will receive capecitabine and anlotinib as maintenance therapy until tumor progression.In order to observe and evaluate the efficacy and safety of Anlotinib Hydrochloride Capsules combined with CAPEOX in treatment of patients with Metastatic Colorectal Carcinoma(mCRC).Primary Efficacy Endpoint: Objective Response Rate (ORR), Secondary Efficacy Endpoints: Progression free survival (PFS) (According to RECIST Version 1.1), Disease Control Rate (DCR) and duration of response(DoR). Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.0.
Interventions
DRUGAnlotinib Hydrochloride
Anlotinib Hydrochloride is a capsule in the form of 8 mg ,10 mg and 12 mg, orally, once daily, 2 weeks on/1 week off.
DRUGCapecitabine
Capecitabine is a capsule in the form of 500 mg, orally, 850 mg/m2, twice daily, 2 weeks on/1 week off.
DRUGOxaliplatin
Oxaliplatin 130 mg/m2,D1
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Zhejiang University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* At least one measurable lesion (the length of spiral CT scan (\> 10mm) meets the requirements of RESCIST 1.1) is found in patients with HCC confirmed by histopathology or cytology or who meet the clinical diagnostic criteria. * ≥ 18 and ≤ 75 years of age * ECOG performance status of 0-1 * No prior treatment for advanced disease (adjuvant therapy allowed) * Life expectancy of at least 3 months * The main organs are functioning normally. * Neutrophils count =/\> 1.5 x 109/L, platelets count =/\> 100 x 109/L, HGB =/\> 90 g/L * total bilirubin =/\< 1.5 x UNL • SGOT and SGPT =/\< 2.5 x UNL (=/\< 5 x UNL in patients with liver metastases) * Creatinine =/\< 1.5 x UNL * Patients who are molecularly diagnosed as having RAS and BRAF wild-type mCRC are Histologically/cytologically confirmed as advanced, colorectal cancer. * Subjects volunteered to join the study, signed informed consent, good compliance, with follow-up.
Exclusion criteria
* Pregnant or lactating women. * Active or untreated CNS metastases as determined by CT or magnetic resonance imaging (MRI) evaluation during screening and prior radiographic assessments. * Patients with hypertension who could not be well controlled by antihypertensive drugs (systolic blood pressure \> 150 mmHg, diastolic blood pressure \> 100 mmHg), patients with myocardial infarction, arrhythmias with poor control (including QTC interval \> 450 ms) and cardiac insufficiency of grade II according to NYHA standard. * with bleeding tendency or undergoing thrombolysis or anticoagulation therapy. * serious uncontrolled intercurrence infection. * Proteinuria ≥ 2+ (1.0g/24hr). * Have evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness. * Within 6 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc. * Have a history of mental illness or psychotropic drug abuse. * Patients with a history of immunodeficiency(or autoimmue disease), or other acquired congenital immunodeficiency diseases, or a history of organ transplantation and hematopoietic stem cell transplantation. * Patients who are allergic to components of Capecitabine preparations, Oxaliplatin injection and anlotinib preparations. * According to the researchers' judgment, there are serious concomitant diseases that endanger patient safety or prevent patients from completing the study. * Patients who have received prior systemic chemotherapy, targeted therapy, immunity therapy or any medication within 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate(ORR) | Every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | using RECIST version 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | using RECIST version 1.1 |
| Disease control rate (DCR) | every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | using RECIST version 1.1 |
| Duration of Response (DoR) | every 2 weeks until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | using RECIST version 1.1 |
| Safety: NCI CTC AE Version 4.0.3 | from day 1 of first dosing to 30 days after permanent discontinuation of Anlotinib | Safety will be evaluated by incidence, severity and outcomes of adverse events (AEs) and categorized by severity in accordance with the NCI CTC AE Version 4.0.3 |
Countries
China
Outcome results
None listed